During these unprecedented times, as the global spread of COVID-19 disrupts life around the world, AGC Biologics is committed to keeping our employees safe as we work to provide our customers with the lifesaving products they need.
We are taking every precaution to help minimize the spread of COVID-19 by working every day to ensure proactive establishment and implementation of guidelines, protocols and other measures to protect our employees and visitors.
We continue to deliver with the critical aim of ensuring business continuity by proactively working with our suppliers to ensure necessary deliveries and stocking. To date, no major issues have arisen. In addition, we are rapidly developing a prioritized safety stock plan that we will execute in close collaboration with our customers.
The effects of this pandemic are undeniable. As a responsible global citizen, we will take all necessary precautions to promote public health and carry out our mission of improving patients’ lives.
AGC Biologics is partnering with CytoDyn Inc. scientists, who discovered that Leronlimab could potentially treat COVID-19 patients. It is currently being tested on critically ill COVID-19 patients in New York.
AGC Biologics is partnering with AdaptVac on a COVID-19 vaccine. AdaptVac accelerates the development of vaccines and therapeutics to fight infectious diseases, cancer, and immunological disorders. Their virus-like particle (VLP) technology could provide a solution to protect against new SARS-CoV-2 infections.
AGC Biologics has announced a partnership with Takara Bio in the fight against COVID-19, collaborating on a prophylaxis DNA vaccine. AGC Biologics will manufacture the plasmid DNA intermediate for the vaccine.
AGC Biologics will manufacture Matrix-M™, the critical adjuvant component of Novavax, Inc’s coronavirus vaccine candidate known as NVX-CoV2373. Matrix-M™ enhances the immune response and stimulates high levels of neutralizing antibodies. AGC Biologics will optimize process development and scale-up production to significantly increase Novavax, Inc’s capacity to deliver doses in 2020 and 2021.
Saiba AG will leverage its patented Cucumber Mosaic Virus VLP platform technology to develop the SARS-CoV-2 vaccine. This recombinant subunit VLP vaccine not only has the potential to rapidly deliver an effective and safe prophylaxis for COVID-19, but also has an economic, scalable, high-yield and large-scale production capability. AGC Biologics will leverage their expertise and competence in VLP manufacturing to contribute to a national supply by year end.
AGC Biologics and Molecular Partners AG will work together to develop a new class of custom-built protein therapeutics known as DARPin® and initiate their multi-specific DARPin® anti-COVID-19 program, MPO420. AGC Biologics will manufacture 100 liter and 1,000 liter scales suitable for development and initial global supply for patients in need.